Sumitomo Pharma Co., Ltd.

This early-stage trial tested a new universal influenza vaccine called fH1/DSP-0546LP in 144 healthy adults aged 18 to 40. The goal was to check safety and how well the vaccine triggers an immune response. Participants received two shots three weeks apart, with different doses or…